XML 64 R35.htm IDEA: XBRL DOCUMENT

Insider Trading Arrangements

3 Months Ended

12 Months Ended

Dec. 31, 2023

During the fiscal quarter ended December 31, 2023, none of the Company's directors or officers informed it of the adoption, modification or termination of a “Rule 10b5-1 trading arrangement” or “non-Rule 10b5-1 trading arrangement,” as those terms are defined in Regulation S-K, Item 408, except as described in the table below:

Name and Title

Date Adopted

Character of Trading Agreement

Aggregate Number of Shares of Common Stock to be (Sold) Purchased Pursuant to Trading Agreement

Duration

Mark S. Schroeder

12/7/2023

Rule 10b5-1 Trading Arrangement

Up to

(17,044)

(1) (2)

12/6/2024 (3)

President, Diagnostics Laboratories and
Chief Operations Officer

Amy B. Summy

12/7/2023

Rule 10b5-1 Trading Arrangement

Up to

(4,916)

(1) (2)

4/1/2024 (3)

Chief Marketing Officer

(1) The figure presented represents the shares to be sold on the vesting of equity awards before reduction for shares to be withheld for tax purposes.

(2) Mr. Schroeder’s plan provides for the exercise of vested stock options and the associated sale of up to 2,119 shares of the Company’s Common Stock.

(3) This trading arrangement permits transactions through and including the earlier to occur of (a) the completion of all sales on the respective order entry date or (b) the date listed in the table.

Rule 10b5-1 Arrangement Adopted

true

Non-Rule 10b5-1 Arrangement Adopted

false

Rule 10b5-1 Arrangement Terminated

false

Non-Rule 10b5-1 Arrangement Terminated

false

Mark S. Schroeder [Member]

Trading Arrangements, by Individual

Name

Mark S. Schroeder